IRON

Announcements

Nothing here yet

Daily updates

• Disc Medicine reported positive Phase 3 APOLLO results for bitopertin in erythropoietic protoporphyria (EPP), meeting both co-primary and all secondary endpoints with significant improvements across key efficacy measures and a favorable safety profile.Oct 19, 2026

FDA designations

Nothing here yet

News

• Disc Medicine reports that bitopertin met all primary and secondary endpoints in the pivotal Phase 3 APOLLO trial in adults and adolescents with erythropoietic protoporphyriaOct 19, 2026
• Disc Medicine completed enrollment in the Phase 3 APOLLO trial of Bitopertin for erythropoietic protoporphyriaMar 27, 2026
• Disc Medicine announces submission of new drug application to US FDA for accelerated approval of bitopertin for patients with erythropoietic protoporphyriaSep 30, 2025
• Disc Medicine announces positive pre-NDA meeting and plans to submit NDA for Bitopertin in erythropoietic protoporphyria (EPP) in October 2025Jul 21, 2025